Top-News
Mittwoch,
30.07.2014 20:00
von
PR Newswire
| Aufrufe: 238
PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M
Mann mit Smartphone und Tablet (Symbolbild).
© metamorworks / iStock / Getty Images Plus / Getty Images
PR Newswire
SCHOFIELD, Wis., July 30, 2014
SCHOFIELD, Wis., July 30, 2014 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCPink:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company is rebranding the LipiGesic® M name along with the name's red and yellow logo. The former will be replaced with the trademarked name MigraPure® going forward. The new name, logo, and color palette of PuraMed's homeopathic, natural migraine pain reliever will be reintroduced into selected segments of the retail marketplace.
"We've been working on this for over a year," said Russell Mitchell, CEO and Chairman of PuraMed BioScience. "We needed to secure the trademark for the name and create the image before we announced the development of the enhanced formula and our product line extensions.
"The new name will be easier for people to remember and pronounce," said Mitchell. "We also believe the new look and color of the logo will convey our 'safe' and 'natural' message at a glance. Preliminary feedback about the change has been positive and we are pleased. We will now have packaging that reflects the excellent product inside."
PuraMed hopes to have the new product, which uses a flavor-enhanced version of the sublingual LipiGesic M formula, new packaging, new price point, and a new website ready for public purchase within the next two months, though promotion and distribution to retailers and targeted wholesale partners will begin earlier.
"The manufacturing order has been placed," said Mitchell. "Our marketing plan is being finalized and as soon as the packaging and the website are ready, we will launch."
MigraPure's fresh look and message will replace the red and yellow LipiGesic logo. A tagline that describes the product will also be a fundamental part of the logo.
"By using a tagline with the image, we can make a stronger statement and leave no doubt in the consumer's mind about what MigraPure is or what it does, which is also an improvement," said Mitchell. "During the re-launch, we will also reference LipiGesic M on the packaging and other marketing materials in order to maintain a connection with our clinical trial data and our current customer base."
Development of the gel, packaging, and launch of the website are the first steps in the rebranding effort. PuraMed plans to continue to sell LipiGesic M under the old label until the new product is available.
A version of the new logo can be seen at www.lipigesic.com/MigraPure.
About MigraPure
MigraPure uses the same sublingual feverfew and ginger formula that was clinically tested as LipiGesic M. The flavor of this all-natural, over-the-counter migraine headache pain relief medication has been enhanced, but the active ingredients that stop disabling migraine pain and associated symptoms quickly, are the same. MigraPure's feverfew and ginger gel is non-drowsy and non-habit forming. MigraPure is not associated with rebound headaches. MigraPure has an excellent safety profile and has no reported drug interactions.
About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to rebranding LipiGesic M to MigraPure, PuraMed BioScience plans to launch additional cannabinoid-enhanced, anti-inflammatory, and anxiolytic products as it moves forward in the development of its cannabinoid product line.
Forward-Looking Statements
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
Contact:
PuraMed BioScience, Inc.
Russell Mitchell, Chairman and CEO
715-359-6373
rmitchell@PuramedBioScience.com
www.PuramedBioScience.com
SOURCE PuraMed BioScience, Inc.
Werbung
Mehr Nachrichten zur Puramed Bioscience Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
